Morgan Stanley cuts target for Johnson & Johnson stock from USD 294.00 to USD 292.00
Published on 10/27/2026 at 18:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMorgan Stanley lowers target
- Morgan Stanley cut its Johnson & Johnson price target from USD 294.00 to USD 292.00 on October 15, 2026.
- MedTech sales rose 2.50 percent to USD 8.64 billion in the third quarter of 2026.
- Johnson & Johnson stock costs EUR 239.95 at Lang & Schwarz on October 27, 2026 at 6:11 p.m. CET, unchanged versus the Xetra close of October 27, 2026.
- The USD 1.34 dividend is scheduled for December 8, 2026, with November 24, 2026 as the ex-dividend date.
Johnson & Johnson (ISIN US4781601046) stock faces a lower analyst target after Morgan Stanley cut its price objective from USD 294.00 to USD 292.00 in a report dated October 15, 2026, as MarketBeat reported. At Lang & Schwarz, the stock was trading at EUR 239.95 on October 27, 2026 at 6:11 p.m. CET, unchanged versus the Xetra close of October 27, 2026 at EUR 239.95.
MedTech grew 2.50 percent
The operating picture is mixed across Johnson & Johnson's two main businesses. In the third quarter of 2026, MedTech sales rose 2.50 percent year over year to USD 8.64 billion, while Innovative Medicine sales increased 7.70 percent to USD 16.76 billion, according to Johnson & Johnson on October 13, 2026.
The same release reported adjusted earnings per share of USD 2.59 for the third quarter, down 7.50 percent from USD 2.80 a year earlier. GAAP net earnings fell to USD 210.00 million from USD 5.15 billion, reflecting litigation-related and acquisition items identified in the release.
Stock position at USD 267.50
On the NYSE, the stock last traded at USD 267.50 on October 27, 2026 at 1:14 p.m. ET. Its 52-week range was USD 184.66 to USD 281.07, and trading volume reached 2,091,345 shares. The current US price was 4.83 percent below the 52-week high, calculated from the same figures.
Johnson & Johnson had a market capitalization of USD 644.0 billion and a price-to-earnings ratio of 40.53 as of October 27, 2026. The valuation leaves the Morgan Stanley target USD 24.50, or 9.16 percent, above the NYSE price.
Dividend dates are set
MarketBeat reported that Johnson & Johnson will pay a USD 1.34 dividend on December 8, 2026. The ex-dividend date and record date are November 24, 2026. The scheduled payment gives income-focused investors a second dated reference alongside the analyst revision.
What the valuation leaves investors
The central tension is visible in the figures. Innovative Medicine is growing faster than MedTech, but adjusted earnings declined in the third quarter and the share price remains below its yearly high. Morgan Stanley's revised target therefore provides a measurable valuation reference rather than a new operating forecast.
Johnson & Johnson stays unchanged
After the Xetra close, Johnson & Johnson stock stood at EUR 239.95 at Lang & Schwarz on October 27, 2026 at 6:11 p.m. CET, unchanged versus the Xetra close of October 27, 2026 at EUR 239.95.
The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.
Johnson & Johnson stock facts
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: JNJ
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 27, 2026, 6:11 p.m. CET): EUR 239.95
- Change versus Xetra close: unchanged
- Xetra close (October 27, 2026): EUR 239.95
- Market capitalization: USD 644.0 billion (as of October 27, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
Market context: Market report S&P 500.
